
Featured
mRNA-4157/V940: The Personalized Cancer Vaccine Rewriting the Rules of Oncology
mRNA-4157/V940, a personalized neoantigen therapy developed by Moderna and Merck, has demonstrated a 44% reduction in recurrence or death risk in high...
Read Full Story →
